<Page>
================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------
FORM 8-K
CURRENT REPORT FILED PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT
(DATE OF EARLIEST EVENT REPORTED): OCTOBER 22, 2002
ENCHIRA BIOTECHNOLOGY CORPORATION
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE 0-21130 04-3078857
(STATE OR OTHER JURISDICTION OF (COMMISSION FILE NUMBER) (I.R.S. EMPLOYER
INCORPORATION OR ORGANIZATION) IDENTIFICATION NO.)
4200 RESEARCH FOREST DRIVE
THE WOODLANDS, TEXAS 77381
(ADDRESS OF PRINCIPAL
EXECUTIVE OFFICES
AND ZIP CODE)
(281) 419-7000
(REGISTRANT'S TELEPHONE
NUMBER, INCLUDING AREA
CODE)
----------------
================================================================================
<Page>
ITEM 5. OTHER EVENTS
On October 22, 2002, Enchira Biotechnology Corporation (the "Company")
issued a press release announcing that the Nasdaq Listing Qualifications Panel
has declined the Company's request for additional time to regain compliance with
the Nasdaq SmallCap listing requirements. Accordingly, the Panel determined to
delist the Company's securities from the Nasdaq Stock Market effective with the
open of business October 22, 2002. Efforts are underway for the stock to begin
trading on the OTC Bulletin Board.
The press release disclosing such determination is filed as an exhibit to
this Current Report on Form 8-K and is incorporated by reference herein.
ITEM 7. EXHIBITS
Exhibit 99.1 -- Press Release
<Page>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ENCHIRA BIOTECHNOLOGY CORPORATION
Date: October 22, 2002.
By: /s/ PAUL G. BROWN, III
---------------------------------------------
Paul G. Brown, III
President, Chief Financial Officer and
Vice President, Finance and Administration